Immunotherapy
Advanced treatment that harnesses and strengthens the body’s own immune system to recognise and destroy cancer cells — a cornerstone of modern, personalised cancer care.
- Immune Checkpoint Inhibitor Therapy
- Biomarker Testing (PD-L1, MSI, TMB)
- Combination Immunotherapy Regimens
- Day-Care & Infusion Services
- Immune-Related Side-Effect Management
Overview
Empowering the body's own defences against cancer
Immunotherapy works differently from chemotherapy and targeted therapy — rather than attacking cancer cells directly, it works by removing the “brakes” that allow cancer to hide from the immune system, freeing the body’s own defences to recognise and destroy tumour cells. For certain cancer types, this approach can offer durable, long-lasting responses, and in some cases works well even after other treatments have stopped being effective.
Treatment begins with biomarker testing — assessing markers such as PD-L1 expression, microsatellite instability (MSI), or tumour mutational burden (TMB) — to determine how likely a cancer is to respond to immunotherapy. Based on these results, an appropriate checkpoint inhibitor or combination regimen is selected, given alone or alongside chemotherapy or targeted therapy depending on the cancer type and stage. Throughout treatment, patients are closely monitored not only for disease response but for immune-related side effects, since immunotherapy can occasionally cause the immune system to affect healthy organs, requiring prompt recognition and management.
Because immunotherapy is often one part of a larger treatment plan, every case is discussed within a multidisciplinary tumour board — medical oncology, surgical oncology, and radiation oncology working together to sequence treatments for the best possible outcome.
What We Offer
Immunotherapy Services
Precision treatments that activate your immune system’s natural ability to fight cancer.
Biomarker & Eligibility Testing
Testing for PD-L1 expression, microsatellite instability, and tumour mutational burden to determine likelihood of response to immunotherapy.
Immune Checkpoint Inhibitor Therapy
Drugs that block proteins such as PD-1, PD-L1, or CTLA-4, releasing the brakes that prevent the immune system from attacking cancer cells.
Combination Immunotherapy Regimens
Carefully sequenced combinations of checkpoint inhibitors, or immunotherapy alongside chemotherapy or targeted therapy, to maximise effectiveness.
Neoadjuvant & Adjuvant Immunotherapy
Immunotherapy given before surgery to shrink tumours or after surgery to reduce the risk of recurrence, depending on cancer type and stage.
Response Monitoring & Protocol Adjustment
Regular imaging and biomarker reassessment throughout treatment to confirm response and adjust therapy if resistance develops.
Immune-Related Side-Effect Management
Close monitoring and prompt treatment of immune-related effects on organs such as the thyroid, lungs, liver, or skin, ensuring safety throughout treatment.
Day-Care Immunotherapy Infusion
Outpatient infusion delivered in a comfortable, monitored setting, allowing most patients to return home the same day.
Vascular Access & Infusion Support
Placement and management of central venous access devices, along with comfortable, monitored infusion services for patients on extended immunotherapy regimens.
Immunotherapy Education & Counselling
One-on-one sessions before starting treatment to explain how immunotherapy works, what to expect, and which symptoms to report promptly — helping patients and families feel prepared and confident throughout care.
Our Approach
The Immunotherapy Advantage
Harnessing your own immune system, with safety and long-term outcomes in focus.
A clear, supported path from first consultation through to long‑term follow‑up.
Treatment Guided by Biomarker Testing
Eligibility and drug selection are based on PD-L1, MSI, and TMB testing — not applied without evidence the cancer is likely to respond.
Close Monitoring Throughout Treatment
Regular imaging and clinical review track disease response and detect immune-related side effects early, allowing prompt intervention.
Potential for Durable, Long-Lasting Response
For eligible cancers, immunotherapy can offer sustained disease control, in some cases continuing to work well after treatment ends.
Multidisciplinary, Whole-Person Care
Medical oncology, surgical oncology, and radiation oncology coordinate to sequence immunotherapy within your complete treatment plan.
Chemotherapy directly kills rapidly dividing cells, while immunotherapy works by activating your own immune system to recognise and destroy cancer cells, often with a different side-effect profile.
Yes. Testing for markers such as PD-L1, MSI, or TMB helps determine whether your cancer is likely to respond to immunotherapy before treatment begins.
Because immunotherapy activates the immune system broadly, it can occasionally affect healthy organs such as the thyroid, lungs, or liver. These effects are closely monitored for and treated promptly if they occur.
Duration varies by cancer type and response, ranging from a fixed course of infusions to ongoing treatment for as long as it continues to be effective and well-tolerated.
Yes, in many cases immunotherapy is combined with chemotherapy or targeted therapy to improve effectiveness. Your oncologist will determine the right combination for your cancer.
Contact
Discuss Your Treatment Options
Every case is unique. Book a consultation to understand the safest and most personalised path forward for you.
Address
# 69, IOA Complex, Royapettah High Rd, Royapettah, Chennai, Tamil Nadu 600014
info@support.com
Our Number
+(0361) 234 567
